Fairvalue-Calculator Fairvalue-Calculator
EN DE

Coloplast A/S (CLPBY) Fair Value & Analysis

Healthcare · US · Market cap $12.9B

Price$5.70
Fair Value$5.51
Upside-3.3%
Quality95/100
Evidence: High Range $3.44 – $6.89

Fair value as of: Jun 24, 2026

Analysis

Coloplast A/S (CLPBY) currently trades at $5.70, while our model-based Fair Value estimate is $5.51 — implying the stock looks roughly 3.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, t…

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -43% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is Coloplast A/S (CLPBY) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $5.51 versus a price of $5.70 — about −3% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CLPBY?
Our 21-model fair value for Coloplast A/S is $5.51 (as of Jun 24, 2026), built from audited fundamentals. The current price is $5.70.
What is the quality score of CLPBY?
Coloplast A/S has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.